CRITICAL SUCCESS FACTORS OF EFFECTIVE DRUG DEVELOPMENT PROCESS: AN ANALYTICAL STUDY
DOI:
https://doi.org/10.61841/rb22zv69Keywords:
Pharmaceutical industry, Drug development, Contemporary diseases, Science and Technology, AdministrationAbstract
This article is aimed to describe factors which are effective towards the success of drug discovery and their development process. According to the research, there is no single explanation on behalf of this discussion as the content outlines crucial factors on its enhancement. Drug development is very critical process, because it helps to treat contemporary diseases and fight the new ones which are within the human populace. Before a drug can reach to an affected person, it should consider successful and rigorous factors that encourage the pharmaceutical developmental programs decide whether it’s far safe, powerful towards treating the severe circumstances and also help them to, envision the correct dosage as well as the suitable administration path. The mentioned factors in the below section, are several outcome of this research therefore, such theories help pharmaceutical industry to study their capability techniques and encourage them to enhance medical development fulfilment prices and its productivity also. Advancement in sciences and technology is also helping this industry with many unique processes and level, from their ideation to development to its approval. There are many pharmaceutical drug development programs which are based on a global strategy that results to predictable expedited approval outcomes.
Downloads
References
• Alanine, A., Nettekoven, M., Roberts, E., & Thomas, A. W. (2003). Lead generationenhancing the success of drug discovery by investing in the hit to lead
process. Combinatorial chemistry & high throughput screening, 6(1), 51-66.
• Corsini, A., & Ceska, R. (2011). Drug–drug interactions with statins: will pitavastatin
overcome the statins’ Achilles’ heel? Current medical research and opinion, 27(8),
1551-1562.
• Dias, D. A., Urban, S., & Roessner, U. (2012). A historical overview of natural
products in drug discovery. Metabolites, 2(2), 303-336.
• Hoelder, S., Clarke, P. A., & Workman, P. (2012). Discovery of small molecule
cancer drugs: successes, challenges, and opportunities. Molecular oncology, 6(2),
155-176.
• Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early
drug discovery. British journal of pharmacology, 162(6), 1239-1249.
• Kesselheim, A. S., & Darrow, J. J. (2015). FDA designations for therapeutics and
their impact on drug development and regulatory review outcomes. Clinical
Pharmacology & Therapeutics, 97(1), 29-36.
• Khanna, I. (2012). Drug discovery in pharmaceutical industry: productivity challenges
and trends. Drug discovery today, 17(19-20), 1088-1102.
• Mohs, R. C., & Greig, N. H. (2017). Drug discovery and development: Role of basic
biological research. Alzheimer's & Dementia: Translational Research & Clinical
Interventions, 3(4), 651-657.
• Naylor, S., & Chen, J. Y. (2010). Unraveling human complexity and disease with
systems biology and personalized medicine. Personalized medicine, 7(3), 275-289.
• O’Brien, M. K., Kolb, M., Connolly, T. J., McWilliams, J. C., & Sutherland, K.
(2011). Early chemical development at legacy Wyeth Research. Drug discovery
today, 16(1-2), 81-88.
• Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H.,
Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the
pharmaceutical industry's grand challenge. Nature reviews Drug discovery, 9(3), 203-
214.
• Petrova, E. (2014). Innovation in the pharmaceutical industry: The process of drug
discovery and development. Innovation and Marketing in the Pharmaceutical
Industry: Emerging Practices, Research, and Policies, 19-81.
• Robinson, L. E., Stodden, D. F., Barnett, L. M., Lopes, V. P., Logan, S. W.,
Rodrigues, L. P., & D’Hondt, E. (2015). Motor competence and its effect on positive
developmental trajectories of health. Sports medicine, 45, 1273-1284.
• Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the
decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery, 11(3),
191-200.
• Zurdo, J. (2013). Developability assessment as an early de-risking tool for
biopharmaceutical development. Pharmaceutical Bioprocessing, 1(1), 29-50
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
